• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Piramal Pharma Solutions New API Plant in Canada Now Online

    MG America Appoints Claudio Radossi as President

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Sartorius Expands Manufacturing Site in Tunisia

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Piramal Pharma Solutions New API Plant in Canada Now Online

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Grand Opening of Kodiak Sciences’ Bioconjugation Facility

    Vertex Expands Cell and Gene Therapy Footprint
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment

    WCG Appoints Sam Srivastava CEO

    AffyXell Expands Manufacturing Partnership with GenScript ProBio

    ABL and Odimma Therapeutics Enter Development Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    CMC Pharmaceuticals

    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Qosina
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    CMC Pharmaceuticals

    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Qosina
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Challenges and Opportunities in Vaccines Drug Development

    As the uptake in vaccines continues to fall, the general public needs to be better informed.

    Challenges and Opportunities in Vaccines Drug Development
    Related CONTENT
    • A Pharmaceutical Smörgåsbord
    • Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI
    • Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI
    • Supply Chain Disruptions
    • QPS Expands Global Footprint
    Adrian Wildfire, Scientific Director, SGS Life Sciences11.20.19
    Vaccine developers are currently under pressure as the uptake of vaccines falls in most middle and high-income countries as a result of negative comments in press articles or misinformed social media exchanges. This downplaying of the benefits and exaggeration of adverse events associated with vaccination programs has coalesced into an “anti-vax movement.” Diseases such as measles that public health scientists had considered well on the road to eradication, similar to rubella and mumps, are re-emerging, which is unexpected given the proven safety and efficacy profile of existing vaccines.

    The general public needs to be better informed as to relevant risk/benefit analyses for such decisions concerning personal safety as they may have lost the historical knowledge regarding the impact of vaccine preventable infectious diseases such as poxviruses/polio and measles. Individuals may therefore put more emphasis on the risk part of such analyses as being more tangible. Additionally, of on-going concern is the rise of vaccine resistance due to religious beliefs, with falls noted in childhood vaccinations. It is largely thanks to childhood vaccination and wider public health programs that smallpox has been eradicated, polio is on the verge of extinction, and that global levels of pulmonary tuberculosis are falling at the rate of 2% per year; although this needs to accelerate to 4–5% to achieve the 2020 milestones of the End TB Strategy.

    Despite material advances in public health and substantial investments into improving the quality of life for all, at a minimal price per dose, the vaccine and wider pharmaceutical industry does not feel able to celebrate its successes due to the perceived risk of a minority backlash and not least, because it is difficult to celebrate an absence of disease. This sentiment is in sharp contrast to the broad social acceptance and appreciation of antibiotics—the effects of antimicrobials are obvious as they cure a tangible, frequently visible illness. Such is the reliance and ingrained nature of antibiotic usage in the public mind and clinical practice that there is more concern regarding the rise of anti-microbial resistance (AMR) than the threatened loss of herd-immunity to preventable diseases.

    As vaccines primarily prevent an illness initiating or worsening, it is perhaps understandable that coincident illnesses occurring around the time of vaccination are given credence as a side-effect or adverse event associated with the vaccine by some, especially since peaks of disease are seen in the very young and the elderly when vaccination programs are also prioritized. A clear understanding of vaccines and their uses and benefits is essential if we are to recognize the successes of vaccination and promote eradication and control programs at all levels.

    The Immunology of Vaccines
    To support advancements in antigenic priming, especially in the very young, the industry needs access to better immuno-stimulatory and modulatory agents. Alum retains its number one position as the adjuvant of choice for many vaccines as many of the emerging adjuvants are difficult to manufacture or hard to access e.g., QS-21 from the soap bark tree in Chile. More study is also needed into the immunological action of adjuvants in specific populations, especially in those for whom vaccines can be less effective, to improve responses.

    Vaccines that target enteric bacteria, such as the recently licensed cholera vaccine, Vaxchora (a live attenuated cholera bacterium suspension), typically only show limited efficacy (≥80% at 90 days) and protection is often short lived. The same might be said for influenza vaccines, which only confer protection for twelve to eighteen months, demonstrating the problems associated with mucosal pathogens and inducing protective responses. Studying the role of innate and adaptive immunity in enteric disease may thus provide insights into infective agents of the respiratory tract and shared correlates.

    Pressing Disease Needs
    The larger ongoing governmental and not-for-profit programs extant across the globe highlight the most pressing needs in terms of public health interventions and give some visibility of the scale of the problem. For example, the seasonal influenza vaccine, as recommended by the World Health Organization, has not reached expected levels of efficacy (>60% average across all ages) over the past 5-10 years, therefore, vaccines that give an improved breadth of coverage (strains and geography) and protection (incidence and longevity) are essential. Another flu pandemic is inevitable and while there is some consensus that, based on historical evidence, it may be caused by a reassorted H1N1 strain, this is by no means certain. It might equally be an H3N2 or H2N2 pandemic and it is not impossible that it will come from an avian virus that has yet to consistently cross into humans e.g. H5N1 or H7N9, although there is no historical evidence that an adaptation of a highly-pathogenic avian influenza virus to humans e.g. via pigs, is imminent or indeed possible.

    The last pandemic virus, pdmH1N1/09, emerged in 1998 as the North American triple reassortment internal genes (TRIG) strain but was not identified until 2015 despite repeated H1N1/H1N2 infections in humans from 2005 to 2009. Indeed, the assertion by key opinion leaders in 2008 that: “…. the question arises whether the next pandemic (is limited) to only H2 viruses in the near future. The majority of the world’s population (younger than 40 years) has no protective immunity to H2 subtype influenza viruses that circulated between 1957 and 1968…” failed to identify pdmH1N1/09 as the next pandemic influenza strain. This illustrates that even expert predictions can be inaccurate. Epidemic modeling programs are also prone to error even at geographically-limited, local levels, with peak incidence and virus strain (prevalence and timing) the most common outliers.

    All the above leads the vaccine industry to struggle with correctly targeting strains in a timely manner and with culturally acceptable approaches to infectious disease intervention and prophylaxis.
    Another viral pathogen with a high disease burden is the Respiratory Syncytial Virus (RSV). RSV is much underserved in the pediatric population with lower respiratory tract (LRT) infections seen in 4-5 million children annually and more than 125,000 children admitted in the same period for RSV-related illness. The recent failure during Phase 3 trials of the Novavax post-fusion antibody-inducing vaccine was a huge setback and whilst MedImmune’s monoclonal antibody palivizumab (Synagis) has proven preventative properties, at-risk individuals require monthly dosing throughout the RSV season and, as with most large-molecule biologics, is complex and thus expensive to manufacture. An effective, long-lasting RSV vaccine would be hugely beneficial to both pediatric and elderly populations, especially in low and middle-income (LMIC) countries which suffer the highest rates of morbidity and mortality.

    Modeling Disease to Improve Disease Interventions
    Both influenza and RSV lend themselves, to modeling in controlled environments, as do many other respiratory viruses. The controlled human infection model (CHIM) is increasingly utilized to provide efficacy data before moving into later-phase field trials. In vaccine CHIM studies, subjects are dosed or ‘challenged’ with infectious titers of the virus of interest following vaccination and the rate of infection (attack rate) and number and severity of symptoms noted. Such challenges take place within a containment facility to avoid accidental release of the agent into the environment and subjects are monitored and sampled intensively to gather contiguous data regarding both the infectious agent and disease state with an emphasis of subject safety. The CHIM model is being employed to explore other infectious agents; viral, bacterial and even parasitic.

    Malaria is a complex, often intractable disease, and with a rapidly warming climate, areas where malaria-carrying mosquitos are endemic are set to expand. There is a big push from concerned organizations such as the Gates Foundation and the US National Institute of Allergy and Infectious Diseases (NIAID) for accelerated translational research into malaria vaccines and, in the absence of an effective correlate of protection, the development of the Controlled Human Malaria Infection model (CHMI) in the US and Europe has led to such modeling in controlled environments becoming one of the primary investigatory tools in the developmental process. CHMI allows studies to be carried out not only in Western, immuno-naïve cohorts, but also in endemic areas where exposure, often due to long-term or serial infections, is commonplace, thus providing evidence for prime and boost properties to be assessed with a high margin of safety and predictive value of efficacy in the field.

    Epidemics, Pandemics and Outbreaks
    With the rise of anti-microbial resistance and multi-drug-resistant tuberculosis, vaccines are seen as offering real potential in controlling certain acquired bacterial infections. Where approved anti-bacterial vaccines exist e.g., meningococcal meningitis, they can be far more effective than antibiotics in reducing disability-adjusted life years (DALYs), a commonly used measure of disease burden. Pneumococcal vaccines in particular, have been very successful at preventing meningitis and sepsis in specific pediatric populations (<2 years old), but, as catastrophic outbreaks of childhood disease are now so rarely seen, there is the risk of complacency, particularly alongside the rising fear of vaccination.

    The Importance of Improving Challenge Modeling
    The development of challenge agents (CA) to current Good Manufacturing Practice (cGMP) has allowed studies to be performed using well characterized pathogens possessing the same level of purity and safety as demanded for commercial drugs and vaccines. Challenge agents are designed and manufactured to preserve wild-type characteristics and thus emulate natural disease, but with a higher infection rate and a consistent spectrum of symptomologies. Combined with a pre-screened population of healthy volunteers the result of such controlled infections is low-noise data i.e., observations and measurements unencumbered by comorbidity or coinfection effects and where the point of initiation and recovery are both known. During challenge studies the disease state can be monitored alongside correlates such as humoral markers e.g., antibodies or viral or bacterial shedding or blood parasitaemia (malaria), to provide meaningful data regarding endpoints and outcomes.

    In the general public, comorbidities and co-infections are common and may be difficult to compensate for. Challenge studies in healthy populations, screened to exclude those subjects with pre-existing disease, are able to provide highly relevant data including estimates of efficacy and limited safety data (due to small cohort sizes)early in the development cycle and such data may further inform vaccine candidate choices and drug dosing regimens.

    Both inherent and acquired properties of challenge agents, for example changes induced during the manufacturing process, may have direct bearing on the quality of clinical trial results downstream. A number of historical challenge agents suffered from low attack rates at even very high titers (relative to community acquired infections), demonstrated low or intermittent shedding during infection, or resulted in insufficiently pronounced symptoms. Given current CA limitations, researchers utilizing CHIM modelling need access to improved agents that are more representative of those viruses circulating in the community if derived data is to translate into effective therapies in the field. Such agents should offer virulence with parity to wild-type virus and a significant range of symptoms.

    Although the challenge model has achieved a substantial degree of standardization through shared data and debate in the CHIM community, a number of elementary questions remain unanswered such as the low incidence of fever in influenza studies. By adapting CHIM to better mimic real-world disease, it should be possible to improve the predictive value of early phase studies and reduce the number of late phase failures.

    Improving the efficacy of challenge agents requires the assistance of regulators to specify guidelines within which the end users (academia/industry) can work and standards to conform to. Currently, when releasing a new challenge agent as fit-for-purpose, the qualified person (QP) has no specific guidelines within cGMP nor quality standards to adhere to. Each challenge agent’s manufacturing plan is considered on a case-by-case basis by the local regulatory authority with only vaccine manufacturing guidelines available for reference. Live vaccines differ materially in many aspects from challenge agents, not least in the need for the retention of virulence and pathogenesis in CAs. Demands to meet vaccine standards may mean the resulting agent is so avirulent that it is incapable of generating disease correlates necessary. To enable the better use of CHIM to accelerate pipelines, a larger menu of antigenically relevant challenge agents is required. Currently there are only approximately 10 influenza strains in common use, all of which are type A.

    The Hunt for Better Correlates
    Amongst many infectious diseases e.g. influenza, RSV and tuberculosis, there is a concern that a lack of relevant correlates which inform outcomes and endpoints, will lead to delays in the development and approval of new drugs and vaccines. The development of new vaccines is accelerated where reliable correlates of protection (CoP) are available, especially those that provide reliable translational evidence, from animal models through to first-in-human trials and beyond. However, frequently there may be no known CoP, or correlates may show unacceptable strain variability, and not equate to an endpoint.
    Additionally, markers may be non-functional, thresholds for individual versus community protection may differ widely (for example adult and paediatric thresholds) or seroprevalent markers may reflect natural immunity and not inferred or induced responses. Where correlates are measurable and/or quantifiable, values may suffer from intra and inter-assay variability, and   markers may lose prognostic effect over time, may work as complexes, or simply fail in the face of genotypic or phenotypic changes in the target organism. All of which lead to the need for more basic research and a greater understanding of relevant correlate.

    When assaying immune responses to new and existing formulations, it has become apparent that antigenic dosage may not be as important as the reactogenicity, as measured by priming of the immune system and longevity of response. Thus, imprinting at an early age with antigenically relevant, adjuvanted or highly antigenic formulations may preserve recall and efficacy during future challenges. As a final thought, recent evidence suggests that repeated vaccination, with antigenically similar preparations, may actually downregulate the protective antibody responses. This poses questions for the seasonal influenza vaccine but may also lead to improved formulations; often only by asking difficult questions do we find answers to difficult problems. 
    Related Searches
    • it
    • quality
    • Clinical Trial
    • Manufacturing
    Suggested For You
    A Pharmaceutical Smörgåsbord A Pharmaceutical Smörgåsbord
    Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI
    Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI
    Supply Chain Disruptions Supply Chain Disruptions
    QPS Expands Global Footprint QPS Expands Global Footprint
    Guidelines in Toxicology: A Blessing and a Curse Guidelines in Toxicology: A Blessing and a Curse
     GSK Grants Ebola Vaccine License to Sabin Vaccine Institute GSK Grants Ebola Vaccine License to Sabin Vaccine Institute
    Yisheng Receives GMP Certification in China Yisheng Receives GMP Certification in China
    FDA Accepts RedHill Biopharma’s NDA for Talicia FDA Accepts RedHill Biopharma’s NDA for Talicia
    Ziopharm Oncology Achieves Positive Results for Glioblastoma Treatment Ziopharm Oncology Achieves Positive Results for Glioblastoma Treatment
    A Brave New World of Data Integrity A Brave New World of Data Integrity
    The Orphan Promise The Orphan Promise
    CROs May Get a Regulatory Boost CROs May Get a Regulatory Boost

    Related Content

    • A Pharmaceutical Smörgåsbord

      This last issue of the year covers a wide range of pharma topics.
      Tim Wright, Editor 11.20.19

    • Information Technology
      Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI

      Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI

      The proven promise and huge potential of using AI and ML to accelerate drug discovery.
      Lucas Glass, Gary Shorter, and Rajneesh Patil, IQVIA 11.20.19

    • Drug Development | Information Technology
      Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI

      Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI

      The proven promise and huge potential of using AI and ML to accelerate drug discovery.
      Lucas Glass, Gary Shorter, and Rajneesh Patil, IQVIA 10.21.19


    • Supply Chain
      Supply Chain Disruptions

      Supply Chain Disruptions

      The implications of Sandoz’ recent recalls.
      Ed Silverman, Guest Columnist 10.15.19

    • Clinical Trials | CRO News | Drug Development
      QPS Expands Global Footprint

      QPS Expands Global Footprint

      Adds new facilities in The Netherlands and India
      09.19.19

      Trending
      • Cellipont Bioservices Expands Cell Therapy Facility | Contract Pharma
      • Biopharma Manufacturing Facility Construction | Contract Pharma
      • Next-Gen Lab Services | Contract Pharma
      • Pharma Development & Manufacturing Trends | Contract Pharma
      • Reviving Local Production Of Antibiotic Powders | Contract Pharma
      Breaking News
      • Piramal Pharma Solutions New API Plant in Canada Now Online
      • MG America Appoints Claudio Radossi as President
      • Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      • Sartorius Expands Manufacturing Site in Tunisia
      • BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      GOED Creates Infographic Highlighting Omega-3 Health Claims Approved in Europe
      Kyowa Hakko Appoints Dr. Colin Hill to Immuse Scientific Advisory Board
      Expert Consensus Statement: Diet is Best Primary Intervention to Achieve Diabetes Remission
      Coatings World

      Latest Breaking News From Coatings World

      What Are You Reading?
      Teknos Receives EcoVadis Gold Medal for Sustainability Performance
      AkzoNobel and Partners Team Up to Hack Carbon Reduction Challenges
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      MPO's Most-Read Stories This Week—May 21
      Iterative Scopes Expands its Senior Leadership Team
      Viz.ai Raises $100 Million in Series D Funding
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Piramal Pharma Solutions New API Plant in Canada Now Online
      MG America Appoints Claudio Radossi as President
      Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Authentic Beauty Concept Launches Second-Generation ‘Refill Bar’
      HASK Beauty Enters Exclusive Partnership with Amazon
      Garance Doré Launches Made in France Skincare Line
      Happi

      Latest Breaking News From Happi

      P&G Closes HQ Due To Security Threat, Launches New Hair Care Line
      SPF Setting Spray, Lip Contour and Knotless Braids Are Hot Trends: Spate
      Nutrafol Launches Collagen Infusion
      Ink World

      Latest Breaking News From Ink World

      Weekly Recap: Zeller+Gmelin, Sun Chemical and Kornit Top This Week’s News
      Nazdar Celebrates 100 Years with a New Look
      hubergroup Chemicals Exhibits at Paint India for First Time
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Brook + Whittle's new acquisition, SunDance goes to HP and more
      Specialty announces move to new facility
      Mark Andy hosts dealer's open house in Warsaw
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Weekly Recap: Kimberly-Clark to Expand Diaper, Wipes Production in Brazil; The Honest Company to Sell Diapers, Wipes at Walmart & More
      3M to Expand in Nebraska
      Nicely Offers Nonwoven Slitters, Winders
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      ODT's Most Read Stories This Week—May 21
      FDA Clears Anika Therapeutics' X-Twist Knotless Fixation System
      Paragon 28 Rolls Out TenoTac 2.0 Hammertoe and Soft Tissue Repair
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: Graphene Flagship, Japan Display and LG Display Top This Week’s Stories
      Evonik Launches New Processing Aids for PV Wafer Cutting
      NREL Creates Highest Efficiency 1-Sun Solar Cell

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login